BARD1 Life Sciences (BD1)
BARD1 Life Sciences Ltd. engages in the provision of medical services. Its activities will include development and commercialization of BARD1AG Intellectual Property and other intellectual property owned by the company for blood testing for screening and diagnosing of lung cancer at early stages. The company was founded on June 30, 1983 and is headquartered in Subiaco, Australia.
|Market Price at 20-11-2017||$0.01|
|Price to Earnings Ratio||-1.87|
|Market Capitalisation||$3.87 (million)|
|Return on Equity (ROE)||-100.35%|